Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial

Autor: Lale Erdem-Eraslan, Roger Stupp, Pim J. French, Th Gorlia, Gail Ryan, Olivier Chinot, F. Dhermain, J.M.M. Gijtenbeek, Monika E. Hegi, P. A. E. Sillevis Smitt, Johan M. Kros, Maaike J. Vos, Carmen Balana, M. Ben Hassel, M. E. van Linde, Gao Y, Khê Hoang-Xuan, A. von Deimling, Brigitta G. Baumert, A. A. Brandes, Bas Weenink, Roelien H. Enting, Warren P. Mason, M. J. van den Bent
Přispěvatelé: Tsinghua University [Beijing] (THU), Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Instituto de Fisica Corpuscular (IFIC), Consejo Superior de Investigaciones Científicas [Madrid] (CSIC)-Universitat de València (UV), Service de Neuroradiologie [CHU de Bicêtre], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de neurooncologie, Hôpital de la Timone [CHU - APHM] (TIMONE), Service de radiothérapie, CRLCC Eugène Marquis (CRLCC), Ruprecht Karls University Heidelberg, Neurology, Pathology, Tsinghua University [Beijing], Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière ( CRICM ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), IFIC - Instituto de Física Corpuscular, Assistance publique - Hôpitaux de Paris (AP-HP), Hôpital de la Timone [CHU - APHM] ( TIMONE ), CRLCC Eugène Marquis ( CRLCC ), Medical oncology, CCA - Imaging and biomarkers, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Oncology
Male
Cancer Research
PILOCYTIC ASTROCYTOMAS
[SDV]Life Sciences [q-bio]
MGMT METHYLATION
0302 clinical medicine
Immunophenotyping
Pilocytic astrocytoma
OLIGODENDROGLIAL BRAIN-TUMORS
ComputingMilieux_MISCELLANEOUS
VINCRISTINE CHEMOTHERAPY
BELOB
Brain Neoplasms
PHASE-III TRIAL
Glioma
Middle Aged
Prognosis
Gene expression profiling
Progression-Free Survival
3. Good health
Treatment Outcome
030220 oncology & carcinogenesis
Female
Immunophenotype
medicine.drug
Adult
medicine.medical_specialty
ADJUVANT PROCARBAZINE
Other Research Donders Center for Medical Neuroscience [Radboudumc 0]
03 medical and health sciences
All institutes and research themes of the Radboud University Medical Center
Internal medicine
RADIATION-THERAPY
medicine
Biomarkers
Tumor
Temozolomide
Low grade glioma
Humans
Progression-free survival
Antineoplastic Agents
Alkylating
Aged
Intrinsic subtype
EORTC 22033-26033
[ SDV ] Life Sciences [q-bio]
business.industry
CENTRAL-NERVOUS-SYSTEM
Cancer
medicine.disease
RANDOMIZED-TRIAL
Clinical trial
business
Transcriptome
030217 neurology & neurosurgery
Zdroj: Gao, Y, Weenink, B, van den Bent, M J, Erdem-Eraslan, L, Kros, J M, Sillevis Smitt, P A E, Hoang-Xuan, K, Brandes, A A, Vos, M, Dhermain, F, Enting, R, Ryan, G F, Chinot, O, Ben Hassel, M, van Linde, M E, Mason, W P, Gijtenbeek, J M M, Balana, C, von Deimling, A, Gorlia, T, Stupp, R, Hegi, M E, Baumert, B G & French, P J 2018, ' Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial ', European Journal of Cancer, vol. 94, pp. 168-178 . https://doi.org/10.1016/j.ejca.2018.02.023
European Journal of Cancer
European Journal of Cancer, 2018, 94, pp.168-178. ⟨10.1016/j.ejca.2018.02.023⟩
European Journal of Cancer, 94, 168-178. Elsevier Ltd.
European Journal of Cancer, Elsevier, 2018, 94, pp.168-178. 〈10.1016/j.ejca.2018.02.023〉
European Journal of Cancer, 94, pp. 168-178
European Journal of Cancer, Elsevier, 2018, 94, pp.168-178. ⟨10.1016/j.ejca.2018.02.023⟩
European Journal of Cancer, 94, 168-178
European Journal of Cancer, 94, 168-178. Pergamon
European Journal of Cancer, 94, 168-178. ELSEVIER SCI LTD
European journal of cancer (Oxford, England, 94, 168-178. Elsevier Limited
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2018.02.023
Popis: Introduction: The European Organisation for Research and Treatment of Cancer (EORTC) 22033-26033 clinical trial (NCT00182819) investigated whether initial temozolomide (TMZ) chemotherapy confers survival advantage compared with radiotherapy (RT) in low-grade glioma (LGG) patients. In this study, we performed gene expression profiling on tissues from this trial to identify markers associated with progression-free survival (PFS) and treatment response.Methods: Gene expression profiling, performed on 195 samples, was used to assign tumours to one of six intrinsic glioma subtypes (IGSs; molecularly similar tumours as previously defined using unsupervised expression analysis) and to determine the composition of immune infiltrate. DNA copy number changes were determined using OncoScan arrays.Results: We confirm that IGSs are prognostic in the EORTC22033-26033 clinical trial. Specific genetic changes segregate in distinct IGSs: most samples assigned to IGS-9 have IDH-mutations and 1p19q codeletion, samples assigned to IGS-17 have IDH-mutations without 1p19q codeletion and samples assigned to other intrinsic subtypes often are IDH-wildtype. A trend towards benefit from RT was observed for samples assigned to IGS-9 (hazard ratio [HR] for TMZ is 1.90, P = 0.065) but not for samples assigned to IGS-17 (HR 0.87, P = 0.62). We did not identify genes significantly associated with PFS within intrinsic subtypes, although followup time is limited. We also show that LGGs and glioblastomas differ in their immune infiltrate, which suggests that LGGs are less amenable to checkpoint inhibitoretype immune therapies. Gene expression analysis also allows identification of relatively rare subtypes. Indeed, one patient with a pilocytic astrocytoma was identified.Conclusion: IGSs are prognostic for PFS in EORTC22033-26033 clinical trial samples. (C) 2018 Elsevier Ltd. All rights reserved.
Databáze: OpenAIRE
Externí odkaz: